After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility.
Stocks Info
Ocular Therapeutix Inc is listed on the NASDAQ in the Healthcare sector while operating in the Biotechnology industry. The current market capitalization of Ocular Therapeutix Inc is $1.09B. A total of 0.91 million shares were traded on the day, compared to an average of 891.96K shares.
In the most recent transaction, Dugel Pravin sold 21,475 shares of OCUL for 6.87 per share on Feb 24 ’25. After the transaction, the insider now owns 3,520,318 company shares. In a previous transaction on Feb 24 ’25, Heier Jeffrey S. sold 3,061 shares at 6.87 per share. OCUL shares that Chief Scientific Officer owns now total 265,998.
Among the insiders who sold shares, Kaiser Peter disposed of 3,009 shares on Feb 24 ’25 at a per-share price of $6.87. This resulted in the Chief Development Officer holding 210,078 shares of OCUL after the transaction. In another insider transaction, Nayak Sanjay sold 1,895 shares at $6.84 per share on Feb 24 ’25. Company shares held by the Chief Strategy Officer now total 283,485.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. In terms of 52-week highs and lows, OCUL has a high of $11.77 and a low of $4.06.
As of this writing, OCUL has an earnings estimate of -$0.22 per share for the current quarter. EPS was calculated based on a consensus of 5.0 estimates, with a high estimate of -$0.14 per share and a lower estimate of -$0.26.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. OCUL’s latest balance sheet shows that the firm has $164.16M in Cash & Short Term Investments as of fiscal 2021. There were $58.98M in debt and $26.34M in liabilities at the time. Its Book Value Per Share was $2.25, while its Total Shareholder’s Equity was $88.00M.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for OCUL is Buy with a score of 5.00.
